agent

(redirected from Erythropoiesis-stimulating agent)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Encyclopedia, Wikipedia.

Agent

A party appointed to act on behalf of a principal entity or person. In context of project financing, refers to the bank in charge of administering the project financing.

Agent

A person who acts on behalf of an organization or another person. Agents have a fiduciary responsibility to act in the best interests of the principal. Common examples of agents include brokers and attorneys. See also: Agency theory, Agency problem, Agency costs.

agent

An individual or organization that acts on behalf of and is subject to the control of another party. For example, in executing an order to buy or sell a security, a broker is acting as a customer's agent.

Agent.

An agent is a person who acts on behalf of another person or institution in a transaction. For example, when you direct your stockbroker to buy or sell shares in your account, he or she is acting as your agent in the trade.

Agents work for either a set fee or a commission based on the size of the transaction and the type of product, or sometimes a combination of fee and commission.

Depending on the work a particular agent does, he or she may need to be certified, licensed, or registered by industry bodies or government regulators. For instance, insurance agents must be licensed in the state where they do business, and stockbrokers must pass licensing exams and be registered with NASD.

In a real estate transaction, a real estate agent represents the seller. That person may also be called a real estate broker or a Realtor if he or she is a member of the National Association of Realtors. A buyer may be represented by a buyer's agent.

agent

a person or company employed by another person or company (called the PRINCIPAL) for the purpose of arranging CONTRACTS between the principal and third parties. An agent generally has authority to act within broad limits in conducting business on behalf of his or her principal and has a basic duty to carry out the tasks involved with due skill and diligence.

An agent or broker acts as an intermediary in bringing together buyers and sellers of a good or service, receiving a flat or sliding scale commission or fee related to the nature and comprehensiveness of the work undertaken and/or value of the transaction involved. Agents and agencies are encountered in one way or another in most economic activities and play an important role in the smooth functioning of the market mechanism. A stockbroker, for example, acts on behalf of clients wishing to buy and sell financial securities; an estate agent acts as an intermediary between buyers and sellers of houses, offices, etc.; while an insurance broker negotiates insurance cover on behalf of clients with an insurance company. A recruitment agency performs the services of advertising for, interviewing and selecting employees on behalf of a company. In addition to the role of agents as market intermediaries, organizational theorists have paid particular attention to the internal relationship between the employees (‘agents’) and owners (‘principals’) of a company See PRINCIPAL-AGENT THEORY.

agent

a person or company employed by another person or company (called the principal) for the purpose of arranging CONTRACTS between the principal and third parties. An agent thus acts as an intermediary in bringing together buyers and sellers of a good or service, receiving a flat or sliding-scale commission, brokerage or fee related to the nature and comprehensiveness of the work undertaken and/or value of the transaction involved. Agents and agencies are encountered in one way or another in most economic activities and play an important role in the smooth functioning of the market mechanism. See PRINCIPAL-AGENT THEORY for discussion of ownership and control issues as they affect the running of companies. See ESTATE AGENT, INSURANCE BROKER, STOCKBROKER, DIVORCE OF OWNERSHIP FROM CONTROL.

agent

One who acts on behalf of a principal in an agency relationship. See agency for an extended discussion.

References in periodicals archive ?
1) The contract is for delivery of chemotherapy drugs and drug programs as well as erythropoiesis-stimulating agents for the Multi-Regional Hospital in Gorzow Wielkopolski.
In November, the Food and Drug Administration approved major revisions to the boxed warnings and other safety-related changes in erythropoiesis-stimulating agents (ESA) labels, reflecting evidence associating ESAs with an increased risk of tumor progression and lower survival rates in patients with certain cancers.
This suggests that biosimilar erythropoiesis-stimulating agents (ESAs) will experience deeper, as well as more rapid, market penetration in the United States than we've seen in Europe as a whole.
Impact of Iron-Based Binders on the use of IV iron and erythropoiesis-stimulating agents (ESAs): Surveyed nephrologists seem more confident that an iron-based phosphate binder will impact the use of IV iron vs.
The study also associated the use of Tego with a reduction in missed dialysis treatments as well as the use and cost of throbolytics, antibiotics and erythropoiesis-stimulating agents (ESAs), "which could have a substantive financial impact for dialysis providers, particularly in the light of the recent rebasing of Centers for Medicare and Medicaid Services reimbursement rates for dialysis," according to the researchers.
The Food and Drug Administration has revised the boxed warning for erythropoiesis-stimulating agents in response to concern about the potential for complications associated with high doses of such agents.
Lichtin, and 11 other update committee members reviewed and analyzed data on erythropoiesis-stimulating agents (ESAs) from Medline and the Cochrane Collaboration between 2002 and July 2007.
At a joint meeting of the FDA's Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, panelists voted 14 to 5 against changing the labels of erythropoiesis-stimulating agents (ESAs) to state that hemoglobin levels should not exceed about 11 g/dL when treating patients with chronic renal failure who are on dialysis.
July 1, 2014 /PRNewswire/ -- Decision Resources Group finds that patient chart data submitted by surveyed nephrologists in China reveals that, consistent with 2011, the percentage of patients on erythropoiesis-stimulating agents (ESAs) significantly increases as chronic kidney disease (CKD) worsens; however, for stage 3, stage 4 and stage 5 non-dialysis (ND), the percentage of patients on ESAs has declined significantly compared with 2011.
The FDA approved revised boxed warnings and other safety-related product labeling changes for erythropoiesis-stimulating agents (ESAs) which treat certain types of anemia.

Full browser ?